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Central elicitation of itch by morphine may result from 
binding to opiate receptors, mimicking the physiological 
binding of endorphins and enkephalins to these recep-
tors. Pretreatment of normal subjects with naloxone 
hydrochloride resulted in diminution or abolition of his-
tamine-provoked itch. These results suggest an impor-
tant role for central opioid peptides as mediators of the 
itch sensation. 
Itch is a frequently experienced somatic sensation, but its 
underlying physiologic mechanisms remain poorly understood 
[1 ,2]. While itch and pain share common neuroanatomic path-
ways, they are distinct sensory modalities (2,3]. Illustrative of 
this distinction is the alleviation of pain but the aggravation of 
itch by morphine and other opiate alkaloids. Although it has 
been suggested that morphine intensifies itch because of its 
direct h.istamine-releasing effect on tissue mast cells [ 4), some 
experimental observations have indicated a possible direct ac-
t ion on the central nervous system (CNS). Specifically, mor-
phine-provoked apparent itch and scratching have been ob-
served in several animal species after injection into the medulla 
or cerebral cisterns [5,6]. The recent demonstration of opioid 
peptides as well as opiate receptors within the CNS [7,8] 
stimulated our interest in this central itch-provoking action of 
morphine. These opioid peptides, the endorphins and enkeph-
alins, appear to function as neurotransmitters within the CNS 
and are present in high concentrations in areas of the brain and 
spinal cord which are involved with pain perception (9,10]. In 
view of the similarities between pain and itch pathways, we 
wondered whether opiate receptors and peptides might be 
involved in the perception of itch as well as pain. We hypothe-
sized that the central action of morphine in eliciting itch might 
result from its binding to central opiate receptors, thus mimick-
ing the physiological binding of endogenous opioid peptides to 
these receptors. A consequence of this hypothesis is that the 
- pharmacological blockade of these opiate receptors with a 
specific antagonist could prevent the binding of physiologic 
opioid peptides to the receptors and, thereby, possibly bloc!' 
the sensation of itch elicited by peripheral stimuli. In the 
present study, we evaluated the effect of a specific opioid 
antagonist naloxone HCl (N-allylnoroxymorphone) on hista-
mine-provoked itch in human subjects. 
MATERIALS AND METHODS 
The study was conducted in 2 parts. In both pal"ts, itching was 
induced by placing a drop of histamine phosphate solution on the 
washed flexor foreaJ"m of normal human adult volu nteers and gently 
pricking rapidly through this drop with a 27-gauge needle to the level 
of the papillaJ"y dermis. This technique resul ted in an itch sensation at 
a reproducible histamine concentration threshold. All studies were 
performed from 9-ll:OO AM to eliminate diurnal variation in itch 
threshold. 
In the frrst part, 5 normal subj ects age 21-30 yr were identified who 
consistently reported itch to w-r. mg/ ml histamine, but not to sterile 
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normal saline when tested under single-blind conditions wi th steril~ 
normal saline and 10- r. mg/ml histamine phosphate solu tion prickeq 
into the skin of the foreru·m on 6 separate occasions. These subj ect\ 
were then tested on 2 different days in a single-blind paradigm, receiviu~ 
a subcutaneous injection of0.8 mg naloxone on one day and an identic<\{ 
volume of sterile normal saline on the other day. Ten minutes fo llowin~ 
the injection of 1 of the 2 test agents, a solution of w-r. mg/ ml histamin~ 
phosphate was pricked into the skin, and the sensation of itch w~ 
reported over a 3-min period. 
The second part of the study was conducted with 18 additional 
normal subjects, age 21-30 yr, who consistently reported itch to 10-~ 
mg/~1 histamine, but not to sterile normal saline when ~ested uncle~ 
single-blind conditions with sterile normal saline and 10- ·· mg/ ml h is, 
tamine phosphage solution pricked into the skin of the forearm on ~ 
separate occasions. The subjects were tested on 2 consecutive day\ 
under a double-blind crossover paradigm. On each day, seven concen, 
trations of histamine phosphate 10- '', 10- '•, 2 X 10- '•, 5 X 10- '·, 10- 4 , ~ 
X w-", 5 x 10- 4 , mg/ ml were pricked every 10 min in random orde~ 
into different areas of forearm skin. The development of itch was agaii\ 
reported over a 3-min period. Each subject was then injected wit~ 
either 2 ml of normal saline or 0.8 mg of naloxone HCl accord ing to~ 
predetermined randomization schedule, and the series of histamin' 
introductions was repeated in the opposite forearm. On the next day 
the procedure was repeated utilizing the other injection solution. 1 
RESULTS 
Of the 5 subjects who received saline prior to the instillatio1\ 
of histamine phosphate in the single-blind trial , 4 experienceq 
histamine-induced itch . However, when these same subject 
were pretreated with naloxone HCI, none reported itch. 
In the double-blind trial, the threshold concentration of his-
tamine which induced itch was hardly affected by prior saline 
injection increasing from .96 x 10- r. mg/ ml to 1.1 X 10-r, mg/ 
ml. In contrast, after naloxone administration the mean h ista-
mine concentration necessary to induce itch was elevated over 
7-fold compared to the mean baseline histamine concentration 
necessary to elicit itch, from 1.2 X 10- '' mg/rnl to 8.5 X 10-s 
mg/ ml (Table). Three of the eighteen subjects (17%) requ.U·ed 
an increased histamine concentration to elicit itching after 
saline injection, while 17 of the 18 (94%) required an increased 
histamine concentration to stimulate itch after naloxone ad-
ministration. Comparing the 2 treatments, a paired sample 1-
test for the means and a chi-square analysis of the itch threshold 
elevations, both demonstrated that naloxone pretreatment pro· 
duced significantly (p <. 0.001) increased histamine itch thxe h· 
olds as compared to saline pretreatment. The diameter and 
intensity of the wheal and flare reactions, however, were not 
affected by naloxone. 
DISCUSSION 
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The provocation of itch by opiate alkaloids is a well -described 
clinical phenomenon [1]. Feldberg and Sherwood's demonstra-
tion that morphine causes histamine release from mast cell in 
the periphery, suggested a peripheral histaminic mechanism for 
this itching [ 4]. However, the frequent inability of systemic 
antihistamines to provide significant relief from such morphine· 
induced itching, as well as the ability to stimulate apparent itch 
and a scratch response in animals by intracisternal or intra-
medullary injection of morphine [5,6], suggested another non· 
histaminic mechanism for opiate-induced itch. Our results sug-
gest that such a nonhistaminic pathway exists, and can bP 
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Pre- injection thresh· Post- injection thresh· 
old his tamine concen· old histamine concen· 
tration to elicit itch tra t ion lo elicit itc h 
(mg/ ml) (mg/ ml) 
.96 X 10-'· ± 9 X 10 r; l.l X 10-r, ± 5 X JO- n 
1.2 x w-" ± 9 x w-•; 8.5 x w-'· ± 6 x 1 o-'· 
S ubjects with in-
creased post- injec-
tion hislarnine 
threshold 
3/ 18" 
17/ 18 
" In o ne subject tht·eshold histamine concentration decreased. 
effectively blocked with naloxone. This pathway most probably 
involves the mediation of enkephalins and/or endorphins and 
specific central receptors for these endogenous opioid peptides. 
Naloxone HCl, a synthetic congener of oxymorphone, is a 
potent opiate antagonist w!t~ ~ost ~o agoni~ti c_ a~tivity (11]. 
The dosage of naloxone utilized m th1s study ts srmilar to that 
employed to reverse narcotic-induced respiTatory depression. 
Recent reports indicate that administration of naloxone can 
block a variety of behavioral and physiologic effects thought to 
be mediated by endogenous endorphins, including acupuncture 
analgesia (12], brain stimulation analgesia (13], and prolactin 
release (14]. Evaluations of naloxone's actions on pain have 
shown either no effect or enhancement of pain stimuli [15]. The 
results of the present experiments demonstrate a novel effect of 
naloxone in attenuating histamine-induced pruritus and indi-
cate a possible role for endorphins in the pathogenesis of itch. 
The subjective nature of pruritus always poses a difficult 
experimental problem. However, the intradermal introduction 
of histamine to induce pruritus has been used successfully and 
reproducibly in a number of studies evilluating the influence of 
drugs on itch [16-20). Such techniques involve punctme intro-
duction or intradermal injection of dilute histamine solutions 
[1]. However, since the small fiber neurons conveying the itch 
sensation are in the superficial papillary dermis, intradermal 
injection is frequently too deep to maximally affect such neu-
rons, whereas puncture introduction delivers the histamine 
more precisely to the areas of the papillary dermis possessing 
such nerve endings. Om utilization of this technique coupled 
with the double-blind vehicle controlled paridgm we employed 
therefore provides a suitable method for quantifying prw-itus. 
Cormia's extensive studies [17-19] of histamine-provoked 
itch revealed that the itch threshold is affected by a number of 
variables, most importantly age, condition of the skin, time of 
day, and anatomical area tested. In particular, the itch thresh-
old increased with age, decreased in patients with dermatitis, 
was lower at night than day, and was lower on the leg, inter-
mediate on the forearm and higher on the back. All of these 
variables must be uniform to ensuJ"e reproducible results. Ad-
clitionally, since minor variations in the itch threshold may be 
seen daily and weekly, it is critical to perform a baseline control 
each day prior to any given experiment [18]. 
Previous attempts to elucidate the pathophysiology of itch 
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have focused on peripheral mediators, most prominently his-
tamine [1]. Our results suggest that a central mechanism for 
experiencing the itch sensation is more important than previ-
ously appreciated. Naloxone and related opiate antagonists may 
be of therapeutic value in a variety of pruritic disorders [21]. 
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